Hikma Pharmaceuticals Plc (HIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Hikma Pharmaceuticals Plc (Hikma) is a pharmaceutical company which undertakes the development, manufacturing and marketing of branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular and diabetes, central nervous system, oncology, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma markets its products across Europe, the US, the Middle East and North Africa region. It has manufacturing facilities in the US, Portugal, Germany, Jordan, Algeria, Sudan, Saudi Arabia, Egypt, Tunisia and Morocco. Hikma is headquartered in London, the UK.
Hikma Pharmaceuticals Plc Key Recent Developments
May 03,2017: Hikma Changes Registered Office
Mar 15,2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10,2016: Hikma Pharmaceuticals: Trading Update
Sep 20,2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24,2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
NOTE: Out of security concerns GlobalData requires using corporate email address.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Hikma Pharmaceuticals Plc (Hikma) is a pharmaceutical company which undertakes the development, manufacturing and marketing of branded and non-branded generics and in-licensed products. The company specializes in the therapeutic areas of cardiovascular and diabetes, central nervous system, oncology, dermatology, genitourinary system, hormones and respiratory system, among others. It offers generics in various dosage forms including tablets, capsules, solutions and suspensions. Hikma markets its products across Europe, the US, the Middle East and North Africa region. It has manufacturing facilities in the US, Portugal, Germany, Jordan, Algeria, Sudan, Saudi Arabia, Egypt, Tunisia and Morocco. Hikma is headquartered in London, the UK.
Hikma Pharmaceuticals Plc Key Recent Developments
May 03,2017: Hikma Changes Registered Office
Mar 15,2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10,2016: Hikma Pharmaceuticals: Trading Update
Sep 20,2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24,2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
NOTE: Out of security concerns GlobalData requires using corporate email address.
SECTION 1 - ABOUT THE COMPANY
Hikma Pharmaceuticals Plc - Key Facts
Hikma Pharmaceuticals Plc - Key Employees
Hikma Pharmaceuticals Plc - Key Employee Biographies
Hikma Pharmaceuticals Plc - Major Products and Services
Hikma Pharmaceuticals Plc - History
Hikma Pharmaceuticals Plc - Company Statement
Hikma Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Hikma Pharmaceuticals Plc - Business Description
Hikma Pharmaceuticals Plc - Corporate Strategy
Hikma Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
Hikma Pharmaceuticals Plc - Strengths
Hikma Pharmaceuticals Plc - Weaknesses
Hikma Pharmaceuticals Plc - Opportunities
Hikma Pharmaceuticals Plc - Threats
Hikma Pharmaceuticals Plc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 03, 2017: Hikma Changes Registered Office
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10, 2016: Hikma Pharmaceuticals: Trading Update
Sep 20, 2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24, 2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
May 24, 2016: Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma’s wholly-owned subsidiary in the US, joins GPhA Board
Mar 16, 2016: Hikma Pharmaceuticals Preliminary Results
Feb 22, 2016: Hikma Appoints John Castellani to Board of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Hikma Pharmaceuticals Plc - Key Facts
Hikma Pharmaceuticals Plc - Key Employees
Hikma Pharmaceuticals Plc - Key Employee Biographies
Hikma Pharmaceuticals Plc - Major Products and Services
Hikma Pharmaceuticals Plc - History
Hikma Pharmaceuticals Plc - Company Statement
Hikma Pharmaceuticals Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
SECTION 2 – COMPANY ANALYSIS
Hikma Pharmaceuticals Plc - Business Description
Hikma Pharmaceuticals Plc - Corporate Strategy
Hikma Pharmaceuticals Plc - SWOT Analysis
SWOT Analysis - Overview
Hikma Pharmaceuticals Plc - Strengths
Hikma Pharmaceuticals Plc - Weaknesses
Hikma Pharmaceuticals Plc - Opportunities
Hikma Pharmaceuticals Plc - Threats
Hikma Pharmaceuticals Plc - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
May 03, 2017: Hikma Changes Registered Office
Mar 15, 2017: Hikma delivers a solid financial performance in 2016 and makes significant strategic progress Strong growth in revenue and core operating profit in constant currency
Nov 10, 2016: Hikma Pharmaceuticals: Trading Update
Sep 20, 2016: Hikma Pharmaceuticals: Board Appointment and Succession
Aug 24, 2016: Hikma delivers solid first half performance and reiterates full year revenue guidance of $2.0 billion to $2.1 billion
May 24, 2016: Michael Raya, CEO of West-Ward Pharmaceuticals, Hikma’s wholly-owned subsidiary in the US, joins GPhA Board
Mar 16, 2016: Hikma Pharmaceuticals Preliminary Results
Feb 22, 2016: Hikma Appoints John Castellani to Board of Directors
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Hikma Pharmaceuticals Plc, Key Facts
Hikma Pharmaceuticals Plc, Key Employees
Hikma Pharmaceuticals Plc, Key Employee Biographies
Hikma Pharmaceuticals Plc, Major Products and Services
Hikma Pharmaceuticals Plc, History
Hikma Pharmaceuticals Plc, Subsidiaries
Hikma Pharmaceuticals Plc, Joint Venture
Hikma Pharmaceuticals Plc, Key Competitors
Hikma Pharmaceuticals Plc, Ratios based on current share price
Hikma Pharmaceuticals Plc, Annual Ratios
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.1)
Hikma Pharmaceuticals Plc, Annual Ratios (Cont.2)
Hikma Pharmaceuticals Plc, Interim Ratios
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Hikma Pharmaceuticals Plc, Performance Chart (2012 - 2016)
Hikma Pharmaceuticals Plc, Ratio Charts
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
COMPANIES MENTIONED
Teva Pharmaceutical Industries Ltd
Sandoz International GmbH
Novartis Pharmaceuticals UK Ltd
Napp Pharmaceuticals Ltd
Lannett Company Inc
Skip to top
Hikma Pharmaceuticals Plc, Performance Chart (2012 - 2016)
Hikma Pharmaceuticals Plc, Ratio Charts
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
Hikma Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
COMPANIES MENTIONED
Teva Pharmaceutical Industries Ltd
Sandoz International GmbH
Novartis Pharmaceuticals UK Ltd
Napp Pharmaceuticals Ltd
Lannett Company Inc